Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:20 2025-06-13 EDT			5-day change	1st Jan Change
114.80 ^EUR	-1.42%		-0.35%	-17.94%

06-12	Merck: EMD Serono Presents Results On Efficacy And Safety Of Enpatoran	RE
06-10	China's Center for Drug Evaluation Accepts Merck KGaA's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor	CI

MERCK KGAA : UBS reiterates its Buy rating

Published on 2024-08-01 at 06:56, updated on 2024-08-01 at 07:45

Already positive, the research from UBS and its analyst Matthew Weston still consider the stock as a Buy opportunity. The target price is unchanged and still at EUR 178.

Latest news about Merck KGaA

Merck: EMD Serono Presents Results On Efficacy And Safety Of Enpatoran	06-12	RE
China's Center for Drug Evaluation Accepts Merck KGaA's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor	06-10	CI
Merck: FDA approves Enflonsia RSV vaccine	06-10	CF
Merck KGaA's Application to Market Tumor Treatment Pimicotinib to Be Reviewed By China	06-10	DJ
Merck KGaA Wins Chinese Approval for Tenosynovial Giant Cell Tumor Treatment	06-10	MT
China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib	06-10	RE
Health insurers in favor of cost containment for drug spending	06-03	DP
MERCK KGAA : JP Morgan reiterates its Buy rating	06-03	ZD
MERCK KGAA : Deutsche Bank maintains a Buy rating	05-30	ZD
Merck KGaA Says Cell Tumor Inhibitor Shows Promise in Late-Stage Trial	05-28	DJ
Bernstein lowers target for Merck KGaA - 'Market Perform'	05-27	DP
MERCK KGAA : Bernstein remains Neutral	05-27	ZD
Equita Keeps Merck KGaA at Buy, Lowers PT	05-26	MT
Merck KGaA - Emd Serono Presents Positive Ph 2 Data For Enpatoran	05-21	RE
Merck KGaA: signs strategic partnership with imec	05-20	CF
AlphaValue/Baader Europe Reduces Merck KGaA's EPS Forecast on US Dollar Weakness	05-20	MT
Merck KGaA to Co-develop Platform for Improved Drug Discovery	05-20	MT
Merck Announces Collaboration With Imec To Develop Disruptive Microphysiological Systems Platform	05-20	RE
German Stocks Jump on EU-UK Post-Brexit Deal	05-19	MT
MERCK : Economic turbulence prompts recalibrations	05-19
MERCK KGAA : Goldman Sachs gives a Buy rating	05-16	ZD
MERCK KGAA : Deutsche Bank remains its Buy rating	05-16	ZD
JPMorgan lowers target for Merck KGaA to €155 - 'Overweight'	05-16	DP
MERCK KGAA : UBS still a buyer after results	05-16	CF
MERCK KGAA : Receives a Buy rating from UBS	05-16	ZD

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (42.1%); - pharmaceutical products (40%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.9%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.7%), Switzerland (1.9%), Europe (22.6%), the United States (25.7%), North America (1.3%), China (13.5%), Asia/Pacific (19.6%), Latin America (7%), Middle East and Africa (3.7%).

Employees

62,604

Sector

Pharmaceuticals

Calendar

06-17 - Silicon Saxony Day

More about the company